Mydecine Innovations partners with contract research organization LeadGen Labs to support its psychedelic drug development efforts

Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) has announced a partnership with LeadGen Labs, a custom synthesis and contract research organization, to support Mydecine’s novel psychedelic drug development efforts and increase the number of novel molecules the company can synthesize concurrently.  Following the announcement of the company’s four initial drug candidates, the Denver-based company said it and LeadGen Labs will work to synthesize novel psychedelic molecules.  Mydecine said LeadGen Labs, which provides expertise in custom synthesis and route design, will work with the company's research and drug design team to target these novel molecular entities and enhanced formulations, including effective dosages and safety. READ: Mydecine Innovations says it is well-funded to advance its IP portfolio and expand clinical trial calendar “We are experiencing a renaissance of medical interest in the classical psychedelics and Mydecine is working to iteratively improve and better understand the potential therapeutic benefits of these known and unknown molecules,” said Rob Roscow, Mydecine’s chief science officer, in a statement.  “We are excited to begin production on these novel patent-pending molecules that hold the promise of improving the therapeutic use of psychedelics through enhanced safety and dosage control. Additionally, the initial batch of novel molecules we will research represent just the first of numerous families of molecules, representing potentially dozens of patentable compounds.” Mydecine CEO Josh Bartch noted that its partnership with LeadGen Labs -- complementary to Mydecine’s work with the University of Alberta and Applied Pharmaceutical Innovation -- expands the company’s existing research infrastructure and allows for more rapid scaling of its drug development pipeline and patent strategy. “With the ability to swiftly synthesize and analyze these various families of novel molecules through both partnerships, we are in a strong position to support the latter stages of our drug development pipeline and build upon our intellectual property portfolio that is focused on building upon the value currently present in natural molecules with patentable safety features that will enhance therapy, reduce anxiety and maximize delivery mechanisms,” Bartch said. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham